NASH Diagnostics Industry- Regional Synopsis
APAC Market Analysis
The Asia Pacific nonalcoholic steatohepatitis diagnostics market is projected to hold the largest market share by the end of 2037. The growth of the market can be attributed majorly to the increasing burden of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) in the Asia Pacific is propelling the market growth. According to a study published by the NCBI, prevalent NAFLD cases were projected to increase 6-20% during 2019-2030, while prevalent NASH cases increase 20%-35%.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
2025 Nonalcoholic Steatohepatitis Diagnostics Market is estimated at USD 1.81 billion.
The global nonalcoholic steatohepatitis diagnostics market size was valued at over USD 1.52 billion in 2024 and is predicted to grow at a CAGR of more than 23.6%, surpassing USD 23.88 billion by 2037.
Asia Pacific is expected to hold a leading industry share, fueled by the rising NAFLD and NASH burden in the region.
The major players in the market include Echosen, Prometheus Laboratories, Genfit, Siemens Medical Solutions USA, Inc., BioPredictive, Quest Diagnostics Incorporated., Meridian Bioscience, Inc., Laboratory Corporation of America Holdings, Bristol-Myers Squibb Company, One Way Liver SL.
